Cancer Care: Review of Bladder Cancer Quality Performance Indicators
Overview
We welcome your views on the Draft Revised Bladder Cancer Quality Performance Indicator Engagement Document.
Please provide comments whether they be on all individual Quality Performance Indicators or only those relevant to you.
In particular we are looking for comments on:
- The appropriateness of the QPIs that have been developed.
- The target levels that have been set.
- Feasibility of measuring the QPIs identified in a meaningful and comparative way (i.e. ‘like for like’ comparison).
All comments are welcome, whether they are positive or negative. Comments can be submitted anonymously however we would be grateful if you could provide contact details, should any further clarification on comments be required.
Why your views matter
National Cancer Quality Performance Indicators (QPIs) were developed to drive continuous quality improvement in cancer care across NHSScotland. The Bladder Cancer QPIs were first published in January 2014. The QPIs are subject to formal review every 3 years, therefore the second cycle of review has now been undertaken following analysis of Year 6 national comparative data.
In order to ensure success of the National Cancer QPIs in driving quality improvement it is critical that QPIs continue to be clinically relevant and focus on areas which will result in improvements to the quality of patient care.
Wide clinical and public engagement is crucial to ensure wide inclusiveness of clinical colleagues across NHSScotland. It is also vital to include the patients and the public as key stakeholders in this consultation to ensure the acceptability of the Quality Performance Indicators.
What happens next
All responses will be collated for review and decision by the Bladder Cancer Review Group. Those who have participated in the engagement process will receive an overview of the changes made and a copy of the final Bladder Cancer QPI document, ahead of publication in early 2022.
Interests
- Health and Social Care
Share
Share on Twitter Share on Facebook